Completion of Cel-Sci's New Facility Signals That Long Awaited Phase III Trial is Imminent

LOS ANGELES--(Business Wire)--
BioMedReports, the news portal which covers Wall Street's biomedical sector and
delivers financial and investment intelligence to a community of highly informed
investors, was given an exclusive tour of CEL-SCI Corporation's, (NYSE AMEX:CVM)
new, state-of-the-art manufacturing facility near Baltimore, MD where the
potentially ground breaking cancer immunotherapy treatment, Multikine, will be
manufactured to support an upcoming Phase III clinical trial.

Multikine is the company's flagship immunotherapeutic head and neck cancer
treatment and is the first immunotherapeutic agent being developed as a
first-line standard of care cancer treatment. Because it required a very
specific cold-fill process for manufacturing, the Phase III trials have been on
hold as Cel Sci dedicated the majority of their time and resources to build the
new best-in-class production facility.

Additionally, once the facility is validated, Cel Sci will become the only
entity offering the 4°C cold fill on a contract basis, meaning the potential to
bring in significant revenue as an added bonus does exist.

BioMedReports' Vinny Cassano was presented with a unique inside look at the
company's new facility and a complete special report of his tour is available
now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/14683-inside-cel-scis-new-multikine-production-facility.html

Biotech investors interested in accessing the news portal's complete database of
clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial
sector. BioMedReports is not paid, or compensated to report news and
developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com

BioMedReports.Com
M. Davila, Editor, +1-323-472-4480
info@biomedreports.com

Copyright Business Wire 2009